Hospira chief gets a $1.1M raise amid manufacturing revamp

Hospira's ($HSP) board has stuck with F. Michael Ball as he has steered the company through a tough regulatory patch in which it had to invest hundreds of millions of dollars to upgrade its plants. For his efforts, Ball last year came out $1.1 million ahead, with $9.89 million in total compensation, compared with $8.78 million in 2012. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…